JRSS
JRSIS Health Care Corporation0.0230
+0.0030+15%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.95MP/E (TTM)
-Basic EPS (TTM)
-0.10Dividend Yield
0%Recent Filings
10-Q
Q3 FY2024 results
JRSIS Health Care Corporation posted Q3 revenue of $222,922, down 55% y/y from $497,361, while YTD revenue edged up 1% y/y to $1,320,738; gross profit plunged 78% y/y to $26,885 in the quarter (12% margin vs. 24% prior), yet held steady YTD at 20% margin. Operating expenses ballooned 237% y/y to $233,075, fueled by marketing pushes and professional fees, flipping Q3 to an operating loss of $206,190 from prior profit; YTD operating loss widened to $485,814. Diluted EPS tallied $(0.0022) for Q3 and $(0.0052) YTD, aligning with 84.6 million shares and net losses of $188,146 and $435,937 attributable to the company. Cash dwindled to $1,372 amid $826,061 operating outflow, offset by $720,030 financing inflows including $1.3 million in loans and $420,000 VIE contributions; total debt stood at $1.3 million short-term (3.7-4.0% rates, maturing 2025) with $6,311 long-term. The November 2023 reverse acquisition of 85.53% VIE interest in Yongzhou JIT via management agreements shifted focus to smart medical tech, recognizing no goodwill. PRC regulatory uncertainties could hobble VIE enforcement.
10-Q
Q2 FY2024 results
JRSIS Health Care Corporation posted Q2 revenue of $597K, up 77% y/y but down 13% q/q (derived), fueled by a surge in high-margin services to third parties that lifted gross profit to $186K from $40K y/y, though gross margin held at 31%. Operating expenses climbed 83% y/y to $305K, driven by marketing pushes and administrative costs, yielding an operating loss of $119K, narrower than last year's $127K but wider q/q from $161K (derived). Net loss attributable to the company eased to $102K from $106K y/y, with diluted EPS steady at $(0.001) on 84.6M shares. Cash rose to $446K on $816K financing inflows including $416K VIE contributions and $402K loans, yet operations drained $474K, leaving short-term debt at $1.4M. Reverse acquisition of Yongzhou JIT in November 2023 via management agreements secured 85.53% control without cash outlay, recognizing no goodwill. PRC regulatory uncertainties could undermine VIE enforcement.
10-Q
Q1 FY2024 results
JRSIS Health Care Corporation posted Q1 FY2024 revenue of $500,420, up 5% year-over-year from $476,994, yet gross profit plunged 62% to $57,222 as cost of revenue surged 36% to $443,198, squeezing the margin to 11% from 32% amid discounts and higher labor costs. Operating expenses ballooned 195% to $218,128, driven by marketing and administrative outlays, flipping income from operations to a $160,906 loss from last year's $77,524 gain; net loss hit $169,948, or $(0.002) per diluted share on 84.3 million shares, versus $0.001 profit. Cash climbed to $323,611 after $413,267 in financing from loans and share issuance offset $204,937 operating outflow, while short-term debt rose to $1.37 million at fixed rates of 3.65%-4.75%. The November 2023 reverse acquisition of an 85.53% variable interest in Yongzhou JIT via management agreements shifted focus to medical tech vending machines. Cash burn persists. Regulatory uncertainties in PRC could hobble VIE enforcement.
10-K
FY2023 results
JRSIS Health Care Corporation's FY2023 results showed revenues doubling to $3.46 million year-over-year, driven by post-COVID recovery and heightened demand for intelligent medical dispensers, with Q4 contributing strongly through Healthy City project sales that made up about one-third of annual revenue. Gross margins expanded dramatically to 14% from 2%, reflecting normalized pricing after pandemic discounts, while operating expenses dipped 6% to $672K amid R&D streamlining, yielding a narrower net loss of $95K versus $673K in 2022. Q4 momentum accelerated with sequential revenue growth from service contracts and hardware deployments, bolstering cash flow to $517K positive from operations. Liquidity remains tight with $118K cash and $983K short-term debt, but no dividends or buybacks occurred; outlook points to Southeast Asia expansion in 2024. Yet regulatory shifts in China's VIE structures could disrupt quarterly momentum.
8-K
Auditor dismissal and appointment
JRSIS Health Care Corporation dismissed ARK Pro CPA & Co. as its principal independent accountant on December 13, 2023, effective immediately, after engaging them in July without any disagreements or reportable events. The board then appointed HHC as the new auditor for the fiscal year ending December 31, 2023, with no prior consultations on financial matters. This switch ensures seamless audit continuity. ARK Pro concurs with the disclosures.
JBHIF
JB HI-FI
63.21+0.00
JILL
J. Jill, Inc.
14.34+0.51
JL
J-Long Group Limited
6.06+0.10
JUSHF
Jushi Holdings Inc.
0.84+0.11
JYNT
The Joint Corp.
8.93+0.15
RDGT
Ridgetech, Inc.
3.78+0.03
SRXH
SRX Health Solutions, Inc.
0.38+0.07
YJ
Yunji Inc. - American Depositor
1.40-0.09
ZJK
ZJK Industrial Co., Ltd.
2.09+0.12
ZJYL
JIN MEDICAL INTERNATIONAL LTD.
0.19-0.02